MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases

Stock Information for MeiraGTx Holdings plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MeiraGTx Holdings plc

MeiraGTx to Present at the BIO CEO & Investor Conference
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
MeiraGTx to Present at the 37th Annual J.P. Morgan Healthcare Conference
MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson's Disease
MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren's Syndrome and Associated Xerostomia or Xerophthalmia
MeiraGTx Expands Leadership Team with Appointment of Katherine Breedis as Chief Financial Officer
MeiraGTx Enters Collaboration with Johnson & Johnson Innovation to Develop Regulatable Gene Therapy Treatment using MeiraGTx Riboswitch Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.